MYC and Miyoshi myopathy: Furthermore, Farrell et al. demonstrated that FABP inhibitors, BMS3094013 and SBFI-26, represent an effective strategy to target MM progression, both in vitro and in vivo, impacting on oncogenic c-Myc signaling pathway [89].